Abatacept in Early-Stage Rheumatoid Arthritis Patients: Longterm Experience and Efficacy in Routine Clinical Practice

简要总结

主要结局

次要结局

• Clinical disease activity index (CDAI)(Up to 12 months)
• Reason for abatacept treatment initiation as determined by the investigator(At baseline)
• Socio-demographics of participants as determined by the investigator(At baseline)
• Concomitant treatment given with abatacept as determined by the investigator(Up to 12 months)
• Dosage of abatacept as determined by the investigator(Up to 12 months)
• Number of patients previously receiving disease modifying anti-rheumatic drug (DMARD)(Up to 12 months)
• Number of patients with cardiovascular risk factors (smoker, hypertension, diabetes, dyslipidemia)(Up to 12 months)
• Simplified Disease Activity Score (based on 28 joints) (DAS28)(Up to 12 months)
• Number of patients who achieve the first low disease activity score (LDAS), DAS28 ≤ 3.2(Up to 12 months)
• Anti-citrullinated protein antibody (ACPA) titer(At baseline)
• Number of patients with other pathologies (cardiovascular, respiratory, liver, renal, cancer, infections, and immuno-deficiency)(Up to 12 months)
• Number of Adverse Events (AE)(Up to 12 months)
• Evaluator global assessment (EGA)(Up to 12 months)
• Frequency of administration of abatacept(Up to 12 months)
• Number of patients who achieve the first clinically significant Disease Activity Score (DAS)-change (≥ 1.2)(Up to 12 months)
• Patient global assessment (PGA)(Up to 12 months)
• Disease history of participants as determined by the investigator(At baseline)
• Number of patients who achieve the first response to treatment per European League Against Rheumatism (EULAR) response criteria(Up to 12 months)
• Number of patients who achieve the first remission state, DAS28 < 2.6(Up to 12 months)
• Number of Serious Adverse Events (SAE)(Up to 12 months)
• Existence or the absence of radiographic erosions as determined by the investigator by imaging technique(Up to 12 months)
• Rheumatoid factor (RF)(Up to 12 months)
• Health Assessment Questionnaire Disability Index (HAQ-DI)(Up to 12 months)
• Simple disease activity index (SDAI)(Up to 12 months)